Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis drug shows promise in Head-to-Head trial

NCT ID NCT03412747

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called bimekizumab against an existing drug (adalimumab) in 478 adults with moderate to severe plaque psoriasis. The goal was to see if bimekizumab could clear more skin at 16 weeks. Participants received either bimekizumab or adalimumab, and then continued on bimekizumab in a blinded maintenance phase. The trial is complete, and results focus on skin clearance scores like PASI90 and IGA.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

478 people

The number who actually took part.

Started

Jan 2018

Finished

Feb 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be at least 18 years of age * Chronic plaque PSO for at least 6 months prior to the Screening Visit * Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale * Subject is a candidate for systemic PSO therapy and/or phototherapy * Female subject of child bearing potential must be willing to use highly effective method of contraception Exclusion Criteria: * Subject has a known hypersensitivity to any excipients of bimekizumab or adalimumab * Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections * Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection * Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection * Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study * Subject has had previous exposure to adalimumab * Presence of active suicidal ideation or positive suicide behavior * Presence of moderately severe major depression or severe major depression * Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic plaque psoriasis Moderate to severe plaque psoriasis

Contacts and locations

Locations

  • Ps0008 004

    Fremantle, Australia

  • Ps0008 005

    Phillip, Australia

  • Ps0008 007

    Hectorville, Australia

  • Ps0008 008

    East Melbourne, Australia

  • Ps0008 009

    Woolloongabba, Australia

  • Ps0008 010

    Kogarah, Australia

  • Ps0008 203

    Dresden, Germany

  • Ps0008 205

    Osnabrück, Germany

  • Ps0008 207

    Berlin, Germany

  • Ps0008 211

    Hamburg, Germany

  • Ps0008 213

    Mahlow, Germany

  • Ps0008 215

    Lübeck, Germany

  • Ps0008 217

    Schweinfurt, Germany

  • Ps0008 218

    Bonn, Germany

  • Ps0008 220

    Hamburg, Germany

  • Ps0008 251

    Gyula, Hungary

  • Ps0008 252

    Budapest, Hungary

  • Ps0008 254

    Budapest, Hungary

  • Ps0008 255

    Budapest, Hungary

  • Ps0008 256

    Debrecen, Hungary

  • Ps0008 260

    Szeged, Hungary

  • Ps0008 352

    Gdansk, Poland

  • Ps0008 353

    Szczecin, Poland

  • Ps0008 354

    Warsaw, Poland

  • Ps0008 355

    Bialystok, Poland

  • Ps0008 356

    Lublin, Poland

  • Ps0008 359

    Katowice, Poland

  • Ps0008 360

    Lodz, Poland

  • Ps0008 362

    Bialystok, Poland

  • Ps0008 363

    Krakow, Poland

  • Ps0008 364

    Nowa Sól, Poland

  • Ps0008 365

    Wroclaw, Poland

  • Ps0008 366

    Katowice, Poland

  • Ps0008 367

    Wroclaw, Poland

  • Ps0008 371

    Bydgoszcz, Poland

  • Ps0008 372

    Lodz, Poland

  • Ps0008 373

    Wroclaw, Poland

  • Ps0008 401

    Saratov, Russia

  • Ps0008 405

    Saint Petersburg, Russia

  • Ps0008 406

    Yaroslavl, Russia

  • Ps0008 657

    Waterloo, Canada

  • Ps0008 659

    Calgary, Canada

  • Ps0008 660

    Montreal, Canada

  • Ps0008 661

    Peterborough, Canada

  • Ps0008 662

    Toronto, Canada

  • Ps0008 663

    Mississauga, Canada

  • Ps0008 664

    Toronto, Canada

  • Ps0008 669

    Windsor, Canada

  • Ps0008 670

    Windsor, Canada

  • Ps0008 674

    Winnipeg, Canada

  • Ps0008 700

    Seoul, South Korea

  • Ps0008 702

    Gwangju, South Korea

  • Ps0008 754

    Taipei, Taiwan

  • Ps0008 755

    Taipei, Taiwan

  • Ps0008 900

    West Des Moines, Iowa, 50265, United States

  • Ps0008 905

    Overland Park, Kansas, 66215, United States

  • Ps0008 906

    Boca Raton, Florida, 33486, United States

  • Ps0008 908

    East Windsor, New Jersey, 08520, United States

  • Ps0008 917

    Troy, Michigan, 48084, United States

  • Ps0008 924

    Houston, Texas, 77004, United States

  • Ps0008 925

    Brighton, Massachusetts, 02135, United States

  • Ps0008 927

    Los Angeles, California, 90033, United States

  • Ps0008 929

    Portland, Oregon, 97223, United States

  • Ps0008 931

    Dallas, Texas, 75231, United States

  • Ps0008 932

    Oklahoma City, Oklahoma, 73112, United States

  • Ps0008 934

    Washington D.C., District of Columbia, 20037, United States

  • Ps0008 935

    Winston-Salem, North Carolina, 27104-35 20, United States

  • Ps0008 936

    Tampa, Florida, 33624, United States

  • Ps0008 939

    Danbury, Connecticut, 06810, United States

  • Ps0008 940

    Beverly, Massachusetts, 01844, United States

  • Ps0008 943

    San Luis Obispo, California, 93405, United States

  • Ps0008 945

    Greer, South Carolina, 29650, United States

  • Ps0008 951

    Houston, Texas, 77004, United States

  • Ps0008 955

    San Diego, California, 92123, United States

  • Ps0008 957

    Glendale, Arizona, 85308, United States

  • Ps0008 961

    Rocky Mount, North Carolina, 27804, United States

  • Ps0008 967

    Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.